Association of multiple myeloma with different neoplasms: Systematic analysis in consecutive patients with myeloma

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 247-259

  Hasskarl, Jens ^a   Ihorst, Gabriele ^a   De Pasquale, David ^a   Schröttner, Percy ^a   Zerweck, Alf ^a   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

different neoplasms; Incidence rate; multiple myeloma (MM); risk factors

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONFOUNDING VARIABLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GYNECOLOGIC CANCER; HAZARD RATIO; HUMAN; KARYOTYPE; KIDNEY CARCINOMA; LYMPHOMA; MALE; MELANOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; THYROID CANCER; URINARY TRACT CANCER; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 79551627594     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.529207     Document Type: Article

References (25)

1. Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 2000;65:123-127.
2. Kishida T, Yonezawa M, Shibata Y, et al. Risk of colorectal cancer in patients with hematologic disease. J Gastroenterol Hepatol 2000;15:1272-1276.
3. Law IP, Blom J. Second malignancies in patients with multiple myeloma. Oncology 1977;34:20-24.
4. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapyrelated leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389-1398.
5. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2001;85:997-1005.
6. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. 1st ed. Chichester, UK: Wiley; 1995.
7. Gesellschaft der epidemiologischen Krebsregister in Deutschland (GEKID). Krebs in Deutschland 2005/2006.Häufigkeiten und Trends. 7. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg), Berlin, 2010. Available from: . med.uni-erlangen.de/ GEKID/Atlas/Inzidenz/atlas/html
8. Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008;111:4039-4047.
9. Beyersmann J, Gastmeier P, Wolkewitz M, Schumacher M. An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol 2008;61:1216-1221.
10. Pullarkat V, Slovak ML, Dagis A, et al. Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. Ann Oncol 2009;20:2000-2006.
11. Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 2008;26:1850-1857.
12. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108-115.
13. Hemminki K, Chen B. Familial association of colorectal adenocarcinoma with cancers at other sites. Eur J Cancer 2004;40:2480-2487. (Pubitemid 39424964)
14. Khalbuss WE, Fischer G, Ahmad M, Villas B. Synchronous presentation of breast carcinoma with plasmacytoid cytomorphology and multiple myeloma. Breast J 2006;12:165-167.
15. Levi F, Te VC, Randimbison L, La Vecchia C. Cancer risk in women with previous breast cancer. Ann Oncol 2003;14:71-73. (Pubitemid 36150261)
16. Spurdle A, Webb P; Australian National Endometrial Cancer Study. Re: Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol 2008;109:153.
17. Lynch HT, Ferrara K, Barlogie B, et al. Familial myeloma. N Engl J Med 2008;359:152-157.
18. Wright JD, St Clair CM, Deutsch I, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010;116:2486-2492.
19. Krishnan B, Morgan GJ. Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomarkers Prev 2007;16:377-380.
20. Zighelboim I, Babb S, Gao F, Powell MA, Mutch DG, Goodfellow PJ. Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecol Oncol 2007;105: 390-394.
21. Omur O, Ozcan Z, Yazici B, Akgun A, Oral A, Ozkilic H. Multiple primary tumors in differentiated thyroid carcinoma and relationship to thyroid cancer outcome. Endocr J 2008;55:365-372.
22. Pantic M, Schroettner P, Pfeifer D, et al. Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma. Leukemia 2010;24:885-890.
23. Yamaguchi M, Ohno T, Miyata E, et al. Analysis of clonal relationship using single-cell polymerase chain reaction in a patient with concomitant mantle cell lymphoma and multiple myeloma. Int J Hematol 2001;73:383-385.
24. Kristinsson SY, Björkholm M, Goldin LR, et al. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 2009;125:2147-2150.
25. Kristinsson SY, Björkholm M, Andersson TM, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009;94: 1714-1720.